Sunshine Guojian Licenses Global Rights of 707 Project to Pfizer
Deep News
Yesterday
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. announced on October 31 that it has licensed the global rights of its 707 project to Pfizer. The subsequent clinical development will be led by Pfizer, while Sunshine Guojian will continue focusing on the autoimmune disease field.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.